Assessment shows rare vaccine-induced immune thrombotic thrombocytopenia following Ad26.COV2.S administration, highlighting antibodies against platelet factor 4 as key diagnostic markers.
Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare adverse event identified following vaccination with some adenovirus-vectored COVID-19 vaccines, including Ad26.COV2.S. VITT is characterized by the presence of antibodies against platelet factor 4 (PF4).
No takes yet. Share an insight, caveat, or question.
Kristyanto et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: